LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Puma Biotechnology Inc

Затворен

СекторЗдравеопазване

3.24

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.13

Максимум

3.24

Ключови измерители

By Trading Economics

Приходи

-16M

3M

Продажби

-13M

46M

P/E

Средно за сектора

4.59

54.533

EPS

0.1

Марж на печалбата

6.464

Служители

172

EBITDA

-14M

4M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+33.23% upside

Дивиденти

By Dow Jones

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

18M

178M

Предишно отваряне

3.24

Предишно затваряне

3.24

Настроения в новините

By Acuity

26%

74%

62 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Puma Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.05.2025 г., 23:48 ч. UTC

Горещи акции

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22.05.2025 г., 23:07 ч. UTC

Топ новини

Fortescue Energy CEO to Resign in Executive Overhaul

22.05.2025 г., 23:03 ч. UTC

Значими двигатели на пазара

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22.05.2025 г., 23:59 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22.05.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22.05.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.05.2025 г., 23:23 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

22.05.2025 г., 23:23 ч. UTC

Пазарно говорене

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22.05.2025 г., 23:12 ч. UTC

Топ новини

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22.05.2025 г., 21:54 ч. UTC

Топ новини

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2025 г., 20:46 ч. UTC

Придобивния, сливания и поглъщания

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22.05.2025 г., 20:39 ч. UTC

Печалби

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22.05.2025 г., 20:36 ч. UTC

Топ новини

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22.05.2025 г., 20:36 ч. UTC

Топ новини
Печалби

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22.05.2025 г., 20:32 ч. UTC

Топ новини
Печалби

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22.05.2025 г., 20:27 ч. UTC

Топ новини

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22.05.2025 г., 20:20 ч. UTC

Топ новини

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22.05.2025 г., 20:17 ч. UTC

Топ новини

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22.05.2025 г., 20:16 ч. UTC

Печалби

Intchains Group 1Q Rev $18.2M >ICG

22.05.2025 г., 20:15 ч. UTC

Топ новини

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22.05.2025 г., 20:08 ч. UTC

Топ новини
Печалби

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22.05.2025 г., 20:05 ч. UTC

Топ новини

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22.05.2025 г., 20:04 ч. UTC

Печалби

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22.05.2025 г., 20:04 ч. UTC

Печалби

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22.05.2025 г., 20:01 ч. UTC

Печалби

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22.05.2025 г., 20:01 ч. UTC

Печалби

Workday 1Q Net $68M >WDAY

22.05.2025 г., 20:01 ч. UTC

Печалби

Workday 1Q EPS 25c >WDAY

22.05.2025 г., 20:01 ч. UTC

Печалби

Workday 1Q Adj EPS $2.23 >WDAY

Сравнение с други в отрасъла

Ценова промяна

Puma Biotechnology Inc Прогноза

Ценова цел

By TipRanks

33.23% нагоре

12-месечна прогноза

Среден 4.33 USD  33.23%

Висок 7 USD

Нисък 2 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Puma Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

1

Купи

1

Задържане

1

Продай

Техническа оценка

By Trading Central

3.07 / 3.075Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

62 / 382 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.